Crucial Information Coming On GSK's Investor Day Includes Consumer Health Spin-Out Details
Key investors have pledged more patience in CEO Walmsley’s turnaround but they will be expecting a convincing vision of the future, more dynamic, GSK.
You may also be interested in...
CureVac is not throwing in the towel just yet, but the odds are stacked against a successful end result.
GSK reports pandemic-related stockpiling in 2020 combined with a weak cold and flu season in Q1 drove its consumer health sales down 9%, with the sharpest downturn in respiratory products sales. The firm expects in the second half of the year to see “more normal consumer trends.”
GlaxoSmithKline has discontinued treatment with its ICOS agonist feladilimab in the Phase II INDUCE-3 trial upon the recommendation of the study’s data monitoring committee, another setback for the big pharma’s plans to become a major force in the cancer therapy area.